Loading...
•
Jun 30, 2025
Bicycle Q2 2025 Earnings Report
Bicycle Therapeutics reported a wider Q2 2025 loss due to rising R&D and administrative costs amid progress across clinical trials.
Key Takeaways
Bicycle Therapeutics posted a Q2 2025 net loss of $79.0 million on revenue of $2.9 million. Cash reserves remain strong at $721.5 million, supporting its growing clinical pipeline including zelenectide pevedotin and Bicycle Radioconjugates.
Q2 2025 revenue declined to $2.9 million from $9.4 million YoY due to lower collaboration income.
Net loss widened to $79.0 million from $39.8 million in Q2 2024.
R&D expenses rose to $71.0 million, driven by zelenectide pevedotin clinical trials.
Cash and cash equivalents stood at $721.5 million, providing runway into 2028.
Forward Guidance
Bicycle aims to advance its oncology pipeline, including radioconjugates and zelenectide pevedotin, while implementing cost-saving initiatives to extend cash runway.
Positive Outlook
- Zelenectide pevedotin progressing in multiple solid tumor trials.
- Strong cash position supports development through 2028.
- Initial human imaging data for EphA2 radioconjugates expected in 2H 2025.
- Organizational streamlining expected to yield 30% cost savings.
- Expansion of clinical and advisory leadership teams.
Challenges Ahead
- Significant increase in R&D expenses YoY.
- Decline in collaboration revenue from prior year.
- Net loss nearly doubled from Q2 2024.
- No near-term product revenue expected.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...